Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Thumbs up for Glaxo

Article Abstract:

Glaxo has set up the biggest pharmaceutical concern world wide through its merger with Wellcome, and the company's share price has risen since Jan 1995. Glaxo shares are recommended by six brokers, some of whom emphasise cost benefits and synergies from the Glaxo-Wellcome merger. Paribas sees synergy benefits. Lehman Brothers is concerned about the expiry of the Zantac patent, but sees Glaxo stock as likely to perform better than the market as a whole. NatWest Securities sees superior earnings growth for the new company, while ABN Amro Hoare Govett has hopes for Pylorid, a new ulcer drug from the company.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Glaxo Holdings PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Drug deal uncertain

Article Abstract:

A planned merger between Pharmacia and Upjohn has been criticised by some analysts and could lead to legal problems. The merger would create a company worth $13 billion, ranking among to 10 largest drugs companies world wide. Investors could group together and take legal action against Upjohn if the board has received cash offers. Pharmacia is 25% owned by Volvo and a 14% stake is held by the Swedish government. The merger could affect Upjohn employees and the company is the main employer in Kalamazoo.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Mergers, acquisitions and divestments, Pharmacia AB, Upjohn Co., UPJ

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Harsh medicine boosts Fisons' prospects

Article Abstract:

Fisons has sold much of its research activities and has come to specialise in drugs distribution, boosting its cash resources. The company has also reached an agreement with Astra to help retain Fison's research program with reduced costs through funding provided by Astra. Fison's profit for 1996 is forecast at 150 million pounds sterling by Greig Middleton, stockbroker, an increase on a previous forecast of 93 million pounds sterling. The company's shares are recommended for investors in Mar 1995.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Drugs and Druggists' Sundries Wholesalers, Drugs Wholesale, Drug wholesalers, Fisons PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Drugs
Similar abstracts:
  • Abstracts: Tuesday Morning, Inc. Mac Frugal's Bargains Inc. Costco Wholesale Corporation
  • Abstracts: Not just child's play. Eight decades of fun. Golden Tee gets bigger than ever in Watford
  • Abstracts: IT roadmap for GRC. Blog communications weapon. Companies lack blog guidelines
  • Abstracts: Decrease of force capabilities as an index of upper limb fatigue. Optimal work - rest cycles for an isometric intermittent gripping task as a function of force, posture and grip span
  • Abstracts: Japan. France
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.